Last reviewed · How we verify
NCT06294808
Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC
trial in Hepatocellular Carcinoma Resectable in 1,043 participants. Completed in 30 June 2020.
30 June 2020
Quick facts
| Lead sponsor | National Cancer Centre, Singapore |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,043 |
| Start date | 17 July 2017 |
| Primary completion | 30 June 2020 |
| Estimated completion | 30 June 2020 |
| Sites | 2 locations across Singapore |
Conditions studied
- Hepatocellular Carcinoma Resectable — all drugs for Hepatocellular Carcinoma Resectable →
Sponsor
National Cancer Centre, Singapore
Who can join
Adults 21 to 80, any sex, with Hepatocellular Carcinoma Resectable. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Clinical outcomes after surgical resection in HCC is a continuum and is clearly related to tumor burden but needs better definition. The researchers describe the use of the "metro ticket" approach to analyze surgical outcomes over the whole spectrum of anatomically resectable HCC to define overall survival including intermediate stage tumors (BCLC B). The analysis the researchers provide in this study enables the clinician to select the optimal surgical resection candidate based on robust long term survival data. In addition, study compares outcome for open surgery vs laparoscopic surgery, survival outcome for viral and non-viral HCC using Albumin-Bilirubin (ALBI) for more comprehensive study result. On top of that, non-HBV, non-HCV (NBNC) hepatocellular carcinoma (HCC) is generally associated with poorer tumor characteristics. However, it remains unclear whether this leads to worse post-resection survival compared to viral-related HCC. This study evaluates the prognostic impact of viral status and liver function on post-resection survival outcomes between NBNC and viral HCC patients. This retrospective study also aims to determine if HCC of viral and non-viral etiologies have different clinical outcomes after surgical resection when tumor burden and liver function are considered.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Metroticket approach in a retrospective cohort study to predict overall survival after surgical resection for hepatocellular carcinoma.
Hoang MTQ, Koh YX, Sultana R, Allen JC, et al · · 2024 · cited 1× · PMID 39248314 · DOI 10.1097/js9.0000000000001868
Verify or expand the search:
- PubMed search for NCT06294808
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatocellular Carcinoma Resectable
Currently open trials in the same condition.
- NCT06157060 — Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA · recruiting
Other National Cancer Centre, Singapore trials
Trials by the same sponsor.
- NCT07428356 — Histotripsy for Ablation of Liver Tumours in Asia · NA · recruiting
- NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting
- NCT07116161 — Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore · NA · recruiting
- NCT06977360 — Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solutio · NA · recruiting
- NCT06766058 — Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy. · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06294808 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Centre, Singapore
- Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06294808.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing